Comparative Pharmacology
Head-to-head clinical analysis: RAPLON versus SERPATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAPLON versus SERPATE.
RAPLON vs SERPATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, enhancing serotonergic neurotransmission.
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
50 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Terminal half-life of 12-15 hours (range 10-18h) in adults; prolonged in renal impairment (up to 30h in severe cases).
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Primarily renal excretion of unchanged drug (60-80%); biliary/fecal elimination accounts for 15-20%.
Category C
Category C
Antihypertensive
Antihypertensive